According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM ) is $0.17 Billion USD. In 2023 the company made a revenue of $60.28 Million USD an increase over the revenue in the year 2022 that were of $27.14 Million USD. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.